Search PubMed⌕ Search

Biomedical subjects

M Bastos

Publications and source records attributed to M Bastos.

30 records · Page 2Linked to original sources
PubMed1992

[Pulse wave velocity as expression of arterial compliance and its importance in the evaluation of arterial hypertension].

STUDY OBJECTIVE: To determine the arterial compliance through the evaluation of pulse wave velocity. DESIGN: Open study with direct comparison of different groups within a 12 week evaluation period. PATIENTS: 69 patients, 49 with hypertension and 20 normals individuals. INTERVENTIONS: Different groups with the following treatments: Isradipine, Lisinopril, Dilevalol and no therapy. MEASUREMENTS AND MAIN RESULTS: There is marked differences in the pulse wave velocity when hypertensive patients are compared with normal individuals (p < 0.001). In a 12 week therapeutic evaluation there is an improvement in the pulse wave velocity particularly when the arterial pressure was lowered to normal values in the hypertensive patients: Lisinopril (p < 0.005), Isradipine (p < 0.005), Dilevalol (p < 0.025). CONCLUSIONS: It is very easy to evaluate the pulse wave velocity. Arterial compliance, which may be evaluated using the pulse wave velocity, is significantly reduced in hypertensive patients, compared with age-matched control subjects. The use of antihypertensive drugs is associated with changes in arterial compliance. There is a significant decrease in the pulse wave velocity after the administration of ACE inhibitors, calcium channel blockers and beta blockers for an equivalent fall in blood pressure. These observations emphasizes the potential importance of the changes in the large arteries, considered as either an associated factor or a consequence of elevated blood pressure, in the evaluation of the cardiovascular morbidity, and mortality of patients treated for hypertension.

Adult↗
PubMed1989

Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine.

As previously reported, acute cyclosporine-induced nephrotoxicity is characterized by a decline in glomerular filtration rate and a selective intrarenal production of the vasoconstrictor thromboxane (TxA2), but not vasodilator prostaglandin E2 (PGE2), or prostacyclin (PGI2), cyclooxygenase metabolites. Fish oils (FO), that are rich in n-3 polyunsaturated fatty acids have a high affinity for cyclooxygenase but serve as poor substrate inhibit TxA2 synthesis. We have shown that when FO replaces olive oil (OO) as the vehicle for CsA, CsA-induced nephrotoxicity and increased TxA2 synthesis are obviated in rodent models. In this study, we demonstrate that the FO vehicle for CsA does not compromise CsA's immunosuppressive properties as deduced from studies of a delayed-type hypersensitivity (DTH) model in BALB/c mice and in a rat heart transplant model. In fact, concurrent FO administration with CsA actually enhances immunosuppression. A dose of CsA incapable of blunting DTH when injected in OO was suppressive when given in FO. Administration of as little as 0.05 ml of FO vehicle potentiated the suppressive action of CsA. In addition, nonconcurrent dietary supplementation of FO in animals receiving CsA caused an increase in the immunosuppressive action of CsA in DTH. FO alone reduced DTH as compared with OO, but was far less effective than CsA plus FO. Furthermore, doses of CsA (5 mg/kg/day or 1.5 mg/kg/day), which are subtherapeutic when administered with OO, prolonged engraftment of Lewis recipients of Lewis x Brown-Norway F1 hearts when CsA was solubilized with FO. These studies indicate that concurrent administration of CsA and FO potentiates the activity of CsA and thus increases its therapeutic index. Thus, CsA plus FO is potentially a safe, potent antirejection therapy worthy of clinical testing, especially insofar as FO prevents CsA-induced acute nephrotoxicity in the rodent.

Adjuvants, Immunologic↗
PubMed1989

[Hypoglycemia: prevention and treatment].

The main measure against hypoglycaemia in diabetes mellitus is prevention by educating patients, their relatives and close friends. Therapy of a hypoglycaemic reaction depends on its severity cause and type of diabetes. Administration of small molecule sugars (saccharose/glucose) is mandatory. Full recovery is usual depending on the rapidity of diagnosis and treatment. Therapeutic measures for diverse hypoglycaemic situations and some practical considerations in relation to prevention are discussed by the authors.

Diabetes Mellitus, Type 1↗
PubMed1986

Effect of pregnancy on moderate renal failure in reflux nephropathy.

During a 10 year study of women with reflux nephropathy 20 women had plasma creatinine concentrations in the range 0.2-0.4 mmol/l (2.3-4.5 mg/100 ml). Six experienced pregnancies exceeding 12 weeks' gestation. Pregnancy was associated with rapid deterioration in function in all six, resulting in end stage renal failure in four women within two years after delivery despite adequate control of blood pressure. Of the 14 women who did not have a prolonged pregnancy, four had periods of uncontrolled hypertension, all of which were related to non-compliance or loss from follow up, or both. Uncontrolled hypertension was also associated with accelerated renal failure, and all four women progressed quickly to end stage renal failure. The remaining 10 women were observed for from five to 10 years; in all 10 renal function deteriorated slowly, and none reached end stage renal failure within seven years. It is concluded that pregnancy in patients with reflux nephropathy and moderately severe renal failure has a deleterious effect on renal function.

Adult↗
PubMedDate not supplied

Fast titration experiments using heat conduction microcalorimeters.

Thermopile heat conduction calorimeters normally have high time constants. Multistep titration experiments involving fast processes may then require several hours to perform. It is demonstrated that such experiments can be conducted about 10 times faster, without loss of accuracy, by use of a "dynamic correction method". For a new small vessel thermopile conduction calorimeter, injections can be made at 1.5-min intervals.

Calorimetry↗
PubMedDate not supplied

[deficiency of growth hormone in children. Re-evaluation after therapeutic completion].

OBJECTIVE: To assess GH secretion in young adults treated with GH replacement therapy in childhood. PATIENTS AND METHODS: From the 38 patients who concluded treatment with GH, we studied 20 (52.6%), 9 girls and 11 boys. Thirteen had Growth Hormone Deficiency (GHD)-65%, while 7 had Multiple Pituitary Hormone Deficiency (MPHD)-35%. The patients were retested within 6 months to 6 years after completing GH therapy. The mean age (+/- SD) at retesting was 18.1 +/- 2.6 years for those with GHD and 20.8 +/- 2.8 for those with MPHD. At reassessment we performed two provocative tests: insulin tolerance test (ITT) and clonidine test. RESULTS: Seven of the 20 patients retested, retained GH deficiency. Of the 13 patients with GHD, only one maintained the deficiency, while of the 7 patients with MPHD, 6 maintained the deficiency. CONCLUSION: Young adults with GH deficiency treated with this hormone should be retested in order to identify those who are truly GH insufficient adults and may benefit from replacement therapy.

Adolescent↗
PubMedDate not supplied

[Acute thyroiditis].

We review the pathophysiology, clinical features and therapy of acute thyroiditis. Four cases are reported stressing the role of fine needle aspiration for the diagnosis of this clinical entity.

Acute Disease↗
PubMedDate not supplied

[Beneficial effects of added glicazide in patients with type II diabetes mellitus treated with insulin].

The aim of the study was to assess, in patients with non insulin dependent diabetes mellitus (NIDDM), either with previous failure to sulphonylureas or insulin treated since the disease started, if the combination of gliclazide to insulin therapy might induce a reduction of daily insulin requirement. 30 caucasian type II patients used to self-monitoring (11 female, 19 male, mean age 55.78 +/- 8.07) with residual pancreatic function (glucagon induced C-peptide release = 1.01 +/- 0.70 microgram/ml) entered the study. 8 were excluded for non compliance or for high antiinsulin antibodies levels and 4 are still under study. Each patients was given, for 3 months, 240 mg of gliclazide in addition to usual daily dose of insulin. Data presented as mean +/- s.e.m. were analysed with analysis of variance (p less than 0.05). Mean initial values of main parameters were as follows: glycaemia 192.7 +/- 33.1 mg/100 ml, insulinaemia 9.5 +/- 4.5 microUI/ml, daily insulin requirements 33.11 +/- 10.47 U/d, HbA1 C 7.5 +/- 1.7%. Total cholesterol 240.1 +/- 52.2 mg/10 ml, triglycerides 120.6 +/- 60.3 mg/100 ml. After 3 months treatment significant reduction in mean daily insulin requirements (20.78 +/- 16.15 U/d) was observed. In 13 patients (72.2%) while keeping good metabolic control (HbA1 C 7.46 +/- 1.63), insulin therapy was reduced (9 patients) or even stopped (4 patients). In the other 5, insulin was maintained or slightly increased. The increase in glucagon induced C-peptide release (1.41 +/- 0.99 micrograms/ml) did not reach significance, while glycaemia and insulinaemia were not changed (196.0 +/- 34.1 mg/100 ml, 11.02 +/- 5.05 microUI/ml).(ABSTRACT TRUNCATED AT 250 WORDS)

Diabetes Mellitus, Type 2↗
PubMedDate not supplied

[Pregnancy and endocrinopathy. Activity, pathology and results at the outpatient obstetrics-endocrinology clinics of the University of Coimbra Hospitals--January 1980 through December 1988].

The authors have elaborated a statistic survey about the pregnant women with endocrinopathies, that they have examined in the outpatient clinic from January of 1980 to December of 1988. Three hundred and twenty four women were examined in an amount of 2152 (two thousand one hundred and fifty two) observations. The incidence for 100 births was 0.54%. Maternal and fetal mobility and mortality were analysed in correlation with the maternal area of endocrinopathy (Diabetes Mellitus, Thyroid, Hypophysis and Adrenal Glands) and with the necessary therapeutic regimens. At last the A.A. made some considerations about the importance of a team approach in this area of medical care, and applied to the clinicians who work in primary care, to a better collaboration.

Endocrinology↗
PubMedDate not supplied

[Diabetes mellitus after renal transplant].

UNLABELLED: Posttransplant Diabetes Mellitus (PTDM) has traditionally been attributed to therapy with steroids, however with the introduction of Cyclosporine (cya) into clinical practice, an increase in the incidence of PTDM was noted. We studied the prevalence of PTDM in Renal transplant recipients and its clinical characteristics. MATERIALS AND METHODS: 355 patients were submitted to a renal transplant between 30/06/80 and 31/12/92. After stabilization of the doses of the immunosuppressive therapy we considered diabetic patients those with fasting glycemic values > or = 140 mg/dl and those with glycemic values between 100-140 mg/dl were given to an oral glucose tolerance test (WHO criteria 1985). RESULTS: Posttransplant diabetes mellitus occurred in 28 patients (7.9%), 11 females with a mean age of 53.36 +/- 12.75 years and 17 males with a mean age of 51.05 +/- 10.60 years. DISCUSSION: Due to the great prevalence of alterations in glucose tolerance and their adverse effects on the cardio-vascular system, we think that all renal transplant recipients should be screened.

Adult↗